Affinity Asset Advisors, LLC portfolio
Latest available portfolio: Q2 2026 · Holdings as of · Filed · $2,044,832,098 in Form 13F holdings
See latest portfolio changesQuarterly portfolio filings
Choose a quarter to see holdings and changes. Newer portfolio dates appear first.
Estimated additions and reductions value share changes at filing-derived prices; they are not actual trade proceeds or costs.
| Quarter | Holdings | SEC-reported value | Est. additions | Est. reductions | Est. net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 104 | $2,044,832,098 | +$380,134,023 | -$383,043,345 | -$2,909,322 | ROIV, APGE, SYRE, XENE, ERAS | 13F-HR | 13 Aug 2026, 16:14 |
| Q1 2026 | 95 | $1,705,088,311 | +$437,216,690 | -$242,992,806 | +$194,223,884 | APGE, XENE, ERAS, INSM, ROIV | 13F-HR | 14 May 2026, 16:46 |
| Q4 2025 | 86 | $1,391,738,675 | +$406,574,901 | -$378,703,384 | +$27,871,517 | APGE, INSM, ABVX, VTYX, XENE | 13F-HR | 13 Feb 2026, 16:39 |
| Q3 2025 | 86 | $1,074,794,555 | +$322,484,994 | -$123,760,271 | +$198,724,723 | VRNA, INSM, SPY, XENE, MDGL | 13F-HR | 13 Nov 2025, 16:35 |
| Q2 2025 | 77 | $676,265,606 | +$145,795,709 | -$151,129,565 | -$5,333,856 | VRNA, INSM, XENE, ACLX, BPMC | 13F-HR | 13 Aug 2025, 16:16 |
| Q1 2025 | 81 | $638,754,394 | +$174,839,887 | -$94,539,023 | +$80,300,864 | XENE, APGE, VRNA, ACLX, ALKS | 13F-HR | 14 May 2025, 16:51 |
| Q4 2024 | 75 | $640,106,162 | +$106,879,547 | -$92,240,314 | +$14,639,233 | XENE, APGE, ACLX, ALKS, TEVA | 13F-HR | 13 Feb 2025, 16:20 |
| Q3 2024 | 77 | $644,524,697 | +$115,038,898 | -$184,358,920 | -$69,320,022 | XENE, APGE, NUVL, ACLX, ALKS | 13F-HR | 13 Nov 2024, 16:05 |
| Q2 2024 | 86 | $634,889,218 | +$173,984,244 | -$91,214,483 | +$82,769,761 | XENE, APGE, MDGL, ACLX, TEVA | 13F-HR | 14 Aug 2024, 16:06 |
| Q1 2024 | 77 | $615,079,245 | +$225,279,498 | -$206,642,834 | +$18,636,664 | APGE, XENE, MDGL, CRNX, AUTL | 13F-HR | 14 May 2024, 16:30 |
| Q4 2023 | 73 | $501,546,141 | +$170,129,018 | -$77,875,624 | +$92,253,394 | IMGN, CERE, CBAY, MDGL, XENE | 13F-HR | 13 Feb 2024, 16:52 |
| Q3 2023 | 69 | $306,059,520 | +$133,241,832 | -$58,543,224 | +$74,698,608 | APGE, TEVA, CBAY, BRIDGEBIO PHARMA INC, CERE | 13F-HR | 14 Nov 2023, 15:58 |
| Q2 2023 | 62 | $254,100,684 | +$92,357,357 | -$124,515,319 | -$32,157,962 | MDGL, CERE, ESTA, KDNY, TEVA | Restatement | 21 Aug 2023, 16:07 |
| Q1 2023 | 63 | $252,812,252 | +$84,613,539 | -$46,861,414 | +$37,752,125 | KDNY, MDGL, RXDX, MRK, VKTX | 13F-HR | 15 May 2023, 16:08 |
| Q4 2022 | 54 | $218,191,273 | +$62,778,182 | -$105,216,366 | -$42,438,184 | KDNY, MDGL, ESTA, ASND, BMRN | 13F-HR | 13 Feb 2023, 16:04 |
| Q3 2022 | 47 | $216,938,000 | +$70,795,667 | -$40,086,217 | +$30,709,450 | ESTA, KDNY, GBT, SNY, TRAVERE THERAPEUTICS INC | 13F-HR | 14 Nov 2022, 16:28 |
| Q2 2022 | 40 | $182,632,000 | +$32,446,475 | -$69,687,470 | -$37,240,995 | ESTA, KURA, KDNY, NARI, ASND | 13F-HR | 12 Aug 2022, 16:22 |
| Q1 2022 | 48 | $252,212,000 | +$109,081,525 | -$64,038,860 | +$45,042,665 | NARI, MORF, KURA, ASND, SWTX | 13F-HR | 13 May 2022, 16:33 |
| Q4 2021 | 46 | $234,412,000 | +$88,478,777 | -$71,853,842 | +$16,624,935 | MORF, SWTX, VINC, NARI, ZNTL | 13F-HR | 11 Feb 2022, 16:11 |
| Q3 2021 | 66 | $251,208,000 | +$86,799,570 | -$36,192,544 | +$50,607,026 | BBIO, VINC, MORF, NARI, KURA | 13F-HR | 12 Nov 2021, 16:35 |
| Q2 2021 | 62 | $209,935,000 | +$58,969,970 | -$43,774,511 | +$15,195,459 | BBIO, MORF, VINC, NAUT, KURA | 13F-HR | 13 Aug 2021, 16:43 |
| Q1 2021 | 62 | $204,020,000 | +$105,007,596 | -$63,749,502 | +$41,258,094 | BBIO, MORF, CRIS, VINC, KURA | 13F-HR | 14 May 2021, 10:57 |
| Q4 2020 | 56 | $162,553,000 | $0 | $0 | $0 | EIDX, CRIS, BBIO, KURA, VINC | 13F-HR | 12 Feb 2021, 14:04 |
Showing 1-23 of 23 filings.
Manager details and filing context
- Latest 13F filing
- Q2 2026 - 13 Aug 2026
- Latest reported 13F value
- $2,044,832,098
- Largest 13F holdings
-
ROIV APGE SYRE XENE ERAS INSM PRAX ALKS ORKA ANAB AVTX CYTK
+8 more
RVMD ABVX TRAX DNTH STRO NUVL TRVI OVID - Form 13F summary
-
- Affinity Asset Advisors, LLC Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Affinity Asset Advisors, LLC reported 104 equity holdings with a total reported market value of $2,044,832,098 for Q2 2026. Top reported holdings included ROIV, APGE, SYRE, XENE, and ERAS.
- Manager signature
- Andrew Weinstein - Chief Financial Officer and Chief Compliance Officer
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Holdings Value